Alvotech (Alvotech) Debt-to-Revenue : 7.46 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Alvotech Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Alvotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $48.7 Mil. Alvotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1,051.2 Mil. Alvotech's annualized Revenue for the quarter that ended in Mar. 2024 was $147.4 Mil. Alvotech's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 7.46.

Alvotech Debt-to-Revenue Historical Data

The historical data trend for Alvotech's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alvotech Debt-to-Revenue Chart

Alvotech Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

10.16

14.22

9.70

11.76

Alvotech Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial									13.17	51.47	14.27	5.04	7.46

Competitive Comparison of Alvotech's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Alvotech's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alvotech's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alvotech's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Alvotech's Debt-to-Revenue falls into.

Alvotech Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Alvotech's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(47.708	+	1027.766)	/	91.434
	=	11.76

Alvotech's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(48.711	+	1051.178)	/	147.408
	=	7.46

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Alvotech Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Alvotech's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Alvotech (Alvotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alvotech (NAS:ALVO) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

ALVO:Iceland Z45:Germany

Address

9, rue de Bitbourg, Luxembourg, LUX, L-1273

Website

https://www.alvotech.com

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.